Endocyte Inc. (NASDAQ:ECYT)’s share price traded up 1.6% during trading on Wednesday . The company traded as high as $3.12 and last traded at $3.11, with a volume of 84,670 shares trading hands. The stock had previously closed at $3.06.

A number of equities analysts recently commented on the company. Zacks Investment Research upgraded Endocyte from a “sell” rating to a “hold” rating in a report on Wednesday. Credit Suisse Group AG restated a “buy” rating on shares of Endocyte in a report on Tuesday, July 12th. Cowen and Company restated a “buy” rating on shares of Endocyte in a report on Wednesday, May 4th. Finally, Wedbush restated an “outperform” rating and set a $8.00 target price on shares of Endocyte in a report on Wednesday, May 4th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $11.15.

The firm has a 50 day moving average of $3.15 and a 200 day moving average of $3.41. The stock’s market cap is $131.44 million.

Endocyte (NASDAQ:ECYT) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.26) by $0.01. During the same quarter in the prior year, the business earned ($0.25) EPS. Equities analysts predict that Endocyte Inc. will post ($1.12) EPS for the current year.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.